Company & Sponsor Intelligence
Novartis
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials11
Recruiting0
Completed10
Countries5
Therapeutic footprint
adhdalzheimersepilepsyneuromuscularparkinsons
Indexed studies
NCT00141063Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT00275912Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
epilepsy · RussiaPHASE4
epilepsy · RussiaPHASE4
NCT00956410To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
alzheimers · FrancePHASE2
alzheimers · FrancePHASE2
NCT00428389Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT00561392Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
alzheimers · GermanyPHASE4
alzheimers · GermanyPHASE4
NCT00143026Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
parkinsons · AustraliaPHASE4
parkinsons · AustraliaPHASE4
NCT01023685To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT06632730Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
neuromuscular · United StatesCOMPLETED
neuromuscular · United StatesCOMPLETED
NCT00733863Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.
alzheimers · FrancePHASE2
alzheimers · FrancePHASE2
NCT01167335Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT00948766Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
alzheimers · United StatesPHASE4
alzheimers · United StatesPHASE4
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →